Abstract-The DIAdvisor™ is an EC/FP7 funded project aiming at the development of a Blood Glucose prediction device which uses easily available information to optimise the therapy of patients with diabetes.
I. INTRODUCTION
The key objective of diabetes treatment is to maintain the blood glucose at near to normal level. This is a demanding and difficult task for the individual patient and requires extensive involvement from Health Care Providers.
The project objectives are to develop a Blood Glucose Prediction and Treatment Advisory system to assist patients, implement a device platform including vital signs and glucose sensors and improve this system through two consecutive clinical trial iterations.
The objective is eventually to provide a medical device technology that minimises the diabetes-related burden to patients and to healthcare systems by increased patient empowerment.
II. PROJECT DESCRIPTION
The DIAdvisor concept includes non-invasive and minimally invasive sensors providing information regarding the patient, a mathematical model for prediction of short-term blood glucose levels and a hand-held device platform for computation and interface to the patient. In the hands of the patient DIAdvisor will constitute a mobile short-term blood glucose predictor and treatment advisor useful for optimisation of the therapy.
Moreover the system will be able to be connected to the health care system enabling Health Care Providers to interact with patient and intervene if needed.
Although seemingly simple in concept, the problem of glucose prediction in an active individual has to date proved intractable.
The scientific and technical findings of the project will be implemented in a device platform suitable for use in a clinical trial setting. In this way the technology will be validated in several clinical trials in EU.
III. EXPECTED RESULTS & IMPACTS
One main effect of DIAdvisor will be to reduce the negative effects of long-term hyperglycaemia without increased occurrence of hypoglycaemia.
Patient empowerment through DIAdvisor use will contribute in minimising the diabetes-related burden to the Health Care Systems as well as promote a model of selfresponsibility in taking care of one's health.
The expected outcome will represent a sound basis to improve diabetes control and quality of life in large populations of insulin-treated patients in terms of a reduction of debilitating diabetic complications and costly expenses from Health Care Systems.
IV. ACHIEVEMENTS
The DIAdvisor project was initiated on 1-March-2008. To evaluate the user aspects of the concept a user survey has been performed among 24 patients and 21 Health Care Providers. The outcome supports that the DIAdvisor concept addresses real user needs. The study indicates that user preference is highest regarding short term prediction which is well in line with the DIAdvisor concept.
To design the prediction and advisor systems of DIAdvisor, data from many individuals are required. For this, 12 systems including blood glucose (BG), continuous interstitial and percutaneous blood glucose sensing (CGM), Non-Invasive Glucose Measurement (NIGM) and relevant vital sign measurements were developed. These systems were implemented in a data acquisition trial involving 90 patients at 3 clinical sites constituting 900 patients days.
During the trial subjects hospitalised for 3 days were exposed to an intensive sampling scheme including high quality lab analysis of blood glucose and determination of plasma insulin. Further subjects were exposed to various excitations like carbohydrate loads and exercise. Following the hospitalisation subjects carried the sensor systems for 7 days at home collecting data under real life conditions. This database is unique in the sense that all these carbohydrate metabolism relevant parameters are recorded simultaneously and with reference to one timeline.
The comprehensive data from this trial have led to detailed identification of glucose-insulin interactions in various conditions of patient life, including rest, meal intakes and physical exercise. Both type 1 and type 2 diabetic patients have been investigated while treated by multiple-daily insulin injections or insulin pumps. Models have then been built in order to be integrated in glucose prediction and treatment advisory systems. Early in-silico testing has shown promising results indicating that a prediction horizon of more than 20 minutes can be reached.
In parallel a device platform has been developed for running these systems. During early 2010 a first DIAdvisor prototype has been through extensive in-vitro validation and is now undergoing clinical testing.
V. FUTURE WORK
During 2010 the DIAdvisor prototype will be tested in a series of clinical trials in France, Italy and Czech Republic to evaluate the achieved performance.
Results from these trials will be utilised for further improvement of the system. These will be implemented in the device platform and in 2011 a more elaborated and refined version will be further tested in clinical trials.
